thesi updat dont believ anyth fundament
wrong busi compani deliv solid core
growth remark ep expans despit omx nois
howev head narr shift
stock wherebi growth set acceler one
stock tool possibl turn multipl
inflect justifi new thu enter
print trade north ebitda ep
beat rais impress consequ
beat rais miss lower matter
explan good felt littl like old thu
expect investor bit spook result turn
anticip pound flesh taken share tomorrow
thesi realli chang mayb uber bull
less inclin believ upsid case particularli given
definit updat vanadi albeit commentari appear suggest
approv still immin us realli
compani grow market deliv omx
also occasion surpris qs like
roll stick sidelin lower pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
roll stick sidelin
sharpen pencil around sustain euroimmun
growth inclus synergi us entri slope vanadi
ramp price initi feedback right level underli
growth da goe lower forecast
broadli fx modest om base lower pt
feel right line w/ recent rang
core growth despit tougher comp da dx
segment driven high-growth end market grow
greater ytd focus technolog portfolio
rais fy core guid exclud euroimmun
increas focu cross-sel da dx portfolio well
collabor leverag segment capabl assay
develop genom autom workflow digit
chang fy om expans target despit
increas fx hw expect off-set better
product mix product leverag
om pressur unexpect compens cost
fx hw
ep lower vs guidanc due compens cost fx
hw partial off-set higher org growth fy ep
lower result
lower birth rate particularli us china slightli
offset dx growth lsd growth reproduct health
step-down european growth lsd due soft
industri hit food due drought tough
lower revenu bn bn due
increment fx hw off-set improv org
growth euroimmun vs
tax lower vs driven discret tax
ep lower vs ep due unplan
comp pressur increment fx hw
off-set improv org top-line lower tax rate
maintain mm howev state
may pressur
capital-expenditure
mm revenu org growth mm
euroimmun sale fx hw
ep w/ fx hw vs august guidanc
tax rate
continu grow w/ low-teen
autoimmun sale drive growth
infecti diseas allergi instrument sale
antigen detect sale steadi grower
momentum us expans larg lab
support continu growth
expect see full year organ growth
euroimmun
potenti synergist w/ rest portfolio
develop assay zika combin later
flow tech tulip euroimmun capabl
dx core exclud euroimmun w/ euroimmun
dd growth immunodx appli genom lsd
growth reproduct health
strong result tulip haoyuan drive high-
teen growth immunodx
 genom biz front-end sampl prep
continu build momentum genet
implement new lab
euroimmun continu grow w/ low-teen
autoimmun sale drive
infecti diseas allergi instrument sale
antigen detect repres balanc sale
steadi grower
growth momentum us
expect see full year organ growth
euroimmun
emerg market dd driven china india
continu perform pharma biotech
pharma sale spectroscopi
custom focus core drug
instrument high throughput screen
renew focu small molecul
new vivo imag product drove
continu strength onesourc servic busi
strong food product perform spectroscopi lc
mass spec total food ldd
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin octob
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
